| 5-fluorouracil and cardiotoxicity: a review JD Sara, J Kaur, R Khodadadi, M Rehman, R Lobo, S Chakrabarti, ... Therapeutic advances in medical oncology 10, 1758835918780140, 2018 | 366 | 2018 |
| Improved survival in steroid‐refractory acute graft versus host disease after non‐myeloablative allogeneic transplantation using a daclizumab‐based strategy with … R Srinivasan, S Chakrabarti, T Walsh, T Igarashi, Y Takahashi, D Kleiner, ... British journal of haematology 124 (6), 777-786, 2004 | 94 | 2004 |
| Early stage colon cancer: Current treatment standards, evolving paradigms, and future directions S Chakrabarti, CY Peterson, D Sriram, A Mahipal World journal of gastrointestinal oncology 12 (8), 808, 2020 | 91 | 2020 |
| A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis R Nakamura, S Chakrabarti, C Akin, J Robyn, E Bahceci, A Greene, ... Bone marrow transplantation 37 (4), 353-358, 2006 | 72 | 2006 |
| Persisting posttransplantation cytomegalovirus antigenemia correlates with poor lymphocyte proliferation to cytomegalovirus antigen and predicts for increased late relapse and … R Nakamura, M Battiwalla, S Solomon, D Follmann, S Chakrabarti, ... Biology of Blood and Marrow Transplantation 10 (1), 49-57, 2004 | 72 | 2004 |
| Targeted therapies in advanced biliary tract cancer: an evolving paradigm S Chakrabarti, M Kamgar, A Mahipal Cancers 12 (8), 2039, 2020 | 59 | 2020 |
| Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma S Chakrabarti, SH Tella, A Kommalapati, BM Huffman, S Yadav, IB Riaz, ... Journal of gastrointestinal oncology 10 (3), 554, 2019 | 49 | 2019 |
| The promise of circulating tumor DNA (ctDNA) in the management of early-stage colon cancer: a critical review S Chakrabarti, H Xie, R Urrutia, A Mahipal Cancers 12 (10), 2808, 2020 | 44 | 2020 |
| Bolus 5-fluorouracil (5-FU) in combination with oxaliplatin is safe and well tolerated in patients who experienced coronary vasospasm with infusional 5-FU or capecitabine S Chakrabarti, J Sara, R Lobo, R Eiring, H Finnes, J Mitchell, M Hartgers, ... Clinical Colorectal Cancer 18 (1), 52-57, 2019 | 34 | 2019 |
| Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer S Chakrabarti, L Bucheit, JS Starr, R Innis-Shelton, A Shergill, H Dada, ... Journal for immunotherapy of cancer 10 (6), 2022 | 26 | 2022 |
| Local excision for patients with stage I anal canal squamous cell carcinoma can be curative S Chakrabarti, Z Jin, BM Huffman, S Yadav, RP Graham, DM Lam-Himlin, ... Journal of gastrointestinal oncology 10 (2), 171, 2019 | 25 | 2019 |
| Intratumoral CD3+ and CD8+ T-cell densities in patients with DNA mismatch repair-deficient metastatic colorectal cancer receiving programmed cell death-1 blockade S Chakrabarti, LJ Huebner, HD Finnes, A Muranyi, J Clements, S Singh, ... JCO precision oncology 3, 1-7, 2019 | 24 | 2019 |
| Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials FA Sinicrope, S Chakrabarti, P Laurent-Puig, L Huebner, TC Smyrk, ... European Journal of Cancer 144, 101-112, 2021 | 21 | 2021 |
| Fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma: current status, insight on resistance mechanisms and toxicity management S Chakrabarti, HD Finnes, A Mahipal Expert Opinion on Drug Metabolism & Toxicology 18 (1), 85-98, 2022 | 17 | 2022 |
| Outcomes on anti‐VEGFR‐2/paclitaxel treatment after progression on immune checkpoint inhibition in patients with metastatic gastroesophageal adenocarcinoma LA Kankeu Fonkoua, S Chakrabarti, MB Sonbol, PM Kasi, JS Starr, AJ Liu, ... International journal of cancer 149 (2), 378-386, 2021 | 17 | 2021 |
| Kinetics of postoperative circulating cell-free DNA and impact on minimal residual disease detection rates in patients with resected stage I-III colorectal cancer. SA Cohen, PM Kasi, VN Aushev, DL Hanna, GP Botta, S Sharif, ... Journal of clinical oncology 41 (4_suppl), 5-5, 2023 | 14 | 2023 |
| First report of dramatic tumor responses with ramucirumab and paclitaxel after progression on pembrolizumab in two cases of metastatic gastroesophageal adenocarcinoma S Chakrabarti, H Dong, HR Paripati, HJ Ross, HH Yoon The oncologist 23 (7), 840-843, 2018 | 13 | 2018 |
| Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (CtDNA)—Guided Minimal Residual Disease (MRD) Assessment in Colorectal Cancer (CRC) S Chakrabarti, AK Kasi, AR Parikh, A Mahipal Cancers 14 (13), 3078, 2022 | 12 | 2022 |
| Systemic therapy of metastatic pancreatic adenocarcinoma: Current status, challenges, and opportunities S Chakrabarti, M Kamgar, A Mahipal Cancers 14 (11), 2588, 2022 | 11 | 2022 |
| Tas-102: a resurrected novel fluoropyrimidine with expanding role in the treatment of gastrointestinal malignancies S Chakrabarti, G Wintheiser, SH Tella, C Oxencis, A Mahipal Pharmacology & Therapeutics 224, 107823, 2021 | 11 | 2021 |
